Annual Reports in Medicinal Chemistry (eBook, ePUB)
108,95 €
108,95 €
inkl. MwSt.
Sofort per Download lieferbar
54 °P sammeln
108,95 €
Als Download kaufen
108,95 €
inkl. MwSt.
Sofort per Download lieferbar
54 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
108,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
54 °P sammeln
Annual Reports in Medicinal Chemistry (eBook, ePUB)
- Format: ePub
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies. Timely and critical reviews of important topics in medicinal chemistry
- Geräte: eReader
- mit Kopierschutz
- eBook Hilfe
- Größe: 14.99MB
Andere Kunden interessierten sich auch für
- Annual Reports in Medicinal Chemistry (eBook, ePUB)118,95 €
- Annual Reports in Medicinal Chemistry (eBook, ePUB)111,95 €
- Progress in Medicinal Chemistry (eBook, ePUB)133,95 €
- Progress in Medicinal Chemistry (eBook, ePUB)142,95 €
- Annual Reports in Medicinal Chemistry (eBook, ePUB)112,95 €
- Advances in Clinical Chemistry (eBook, ePUB)126,95 €
- Recent Advances in Medicinal Chemistry, Volume 1 (eBook, ePUB)53,95 €
-
-
-
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.
- Timely and critical reviews of important topics in medicinal chemistry
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 472
- Erscheinungstermin: 31. Dezember 2012
- Englisch
- ISBN-13: 9780123972149
- Artikelnr.: 43851222
- Verlag: Elsevier Science & Techn.
- Seitenzahl: 472
- Erscheinungstermin: 31. Dezember 2012
- Englisch
- ISBN-13: 9780123972149
- Artikelnr.: 43851222
Personal Essay
- Reflections on Medicinal Chemistry at Merck, West Point
- My Path in Seeking New Medicines
- Tales of Drug Discovery
- Recent Developments in Targeting Neuroinflammation in Disease
- Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease
- mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
- NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
- Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
- Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
- AMPK Activation in Health and Disease
- Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
- Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
- Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
- Bifunctional Compounds for the Treatment of COPD
- Inflammatory Targets for the Treatment of Atherosclerosis
- Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
- Small-Molecule Antagonists of Bcl-2 Family Proteins
- Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
- Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
- Recent Advances in the Discovery of Dengue Virus Inhibitors
- Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
- HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replicati
Paul S. Anderson
Peter R. Bernstein
M. Ross Johnson
I. Central Nervous System Diseases
Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts
Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal
Harrie J. M. Gijsen and François P. Bischoff
Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher
Kamalesh B. Ruppa, Dalton King and Richard Olson
Lei Zhang and Anabella Villalobos
II. Cardiovascular and Metabolic Diseases
Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey
Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler
Iyassu K. Sebhat and Robert W. Myers
Juan C. Jaen, Jay P. Powers and Tim Sullivan
Philip A. Carpino and David Hepworth
III. Inflammatory Pulmonary and Gastrointestinal Diseases
Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey
Alaric J. Dyckman
Gary Phillips and Michael Salmon
Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi
IV. Oncology
Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia
Paul F. Richardson
Sean P. Brown and Joshua P. Taygerly
Vibhavari Sail and M. Kyle Hadden
Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda
V. Infectious Diseases
Section Editor: John Primeau, Westford, Massachusetts
Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand
Pravin S. Shirude and Shahul Hameed
Personal Essay
- Reflections on Medicinal Chemistry at Merck, West Point
- My Path in Seeking New Medicines
- Tales of Drug Discovery
- Recent Developments in Targeting Neuroinflammation in Disease
- Secretase Inhibitors and Modulators as a Disease Modifying Approach Against Alzheimer's Disease
- mGluR2 Activators and mGluR5 Blockers Advancing in the Clinic for Major CNS Disorders
- NMDA Antagonists of GluN2B Subtype and Modulators of GluN2A, GluN2C and GluN2D Subtypes - Recent Results and Developments
- Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging
- Case History: EliquisTM (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases
- AMPK Activation in Health and Disease
- Type-2 Diabetes and Associated Co-Morbidities as an Inflammatory Syndrome
- Beyond PPARs & Metformin: New Insulin Sensitizers for the Treatment of Type 2 Diabetes
- Recent Advances in the Discovery and Development of Sphingosine-1-Phosphate-1 Receptor Agonists
- Bifunctional Compounds for the Treatment of COPD
- Inflammatory Targets for the Treatment of Atherosclerosis
- Nanotechnology Therapeutics in Oncology - Recent Developments and Future Outlook
- Small-Molecule Antagonists of Bcl-2 Family Proteins
- Notch Pathway Modulators as Anti-Cancer Chemotherapeutics
- Anaplastic Lymphoma Kinase (ALK) Inhibitors for the Treatment of ALK-Positive Cancers
- Recent Advances in the Discovery of Dengue Virus Inhibitors
- Non Fluoro-Quinolone Based Inhibitors of Mycobacterial Type II Topoisomerase as Potential Therapeutic Agents for TB
- HCV Inhibition Mediated through the Nonstructural Protein 5A (NS5A) Replicati
Paul S. Anderson
Peter R. Bernstein
M. Ross Johnson
I. Central Nervous System Diseases
Section Editor: Albert J. Robichaud; Sage Therapeutics, Inc. Cambridge, Massachusetts
Allen T. Hopper, Brian M. Campbell, Henry Kao, Sean A. Pintchovski and Roland G. W. Staal
Harrie J. M. Gijsen and François P. Bischoff
Sylvain Célanire, Guillaume Duvey, Sonia Poli and Jean-Philippe Rocher
Kamalesh B. Ruppa, Dalton King and Richard Olson
Lei Zhang and Anabella Villalobos
II. Cardiovascular and Metabolic Diseases
Section Editor: Andy Stamford, Merck Research Laboratories, Kenilworth, New Jersey
Donald J. P. Pinto, Pancras C. Wong, Robert M. Knabb and Ruth R. R. Wexler
Iyassu K. Sebhat and Robert W. Myers
Juan C. Jaen, Jay P. Powers and Tim Sullivan
Philip A. Carpino and David Hepworth
III. Inflammatory Pulmonary and Gastrointestinal Diseases
Section Editor: David S. Weinstein, Bristol-Myers Squibb R&D, Princeton, New Jersey
Alaric J. Dyckman
Gary Phillips and Michael Salmon
Robert O. Hughes, Alessandra Bartolozzi and Hidenori Takahashi
IV. Oncology
Section Editor: Shelli R. McAlpine, School of Chemistry, University of New South Wales, Sydney, Australia
Paul F. Richardson
Sean P. Brown and Joshua P. Taygerly
Vibhavari Sail and M. Kyle Hadden
Kazutomo Kinoshita, Nobuhiro Oikawa and Takuo Tsukuda
V. Infectious Diseases
Section Editor: John Primeau, Westford, Massachusetts
Jeremy Green, Upul Bandarage, Kate Luisi and Rene Rijnbrand
Pravin S. Shirude and Shahul Hameed